Share this story:

InnovoSIL TM-1 Antimicrobial Silver Works Against Candida auris and Superbugs

Innovotech Inc.

Edmonton, AB - TheNewswire - May 15, 2023 - Innovotech Inc. (TSX-V:IOT) reports that its InnovoSIL™-1 silver periodate antimicrobial compound acts as an excellent antimicrobial against Candida auris.


C. auris is an emerging fungus (yeast) causing a serious global health threat due to its resistance to antibiotic treatments and its tendency to cause severe illness in people with weakened immune systems.  C. auris infections have been associated with 30-60% mortality rates in hospitalized patients.


Coated onto a wound dressing model, InnovoSIL™-1 silver prevented a broad spectrum of microorganisms from adhering to the dressing surface over time under clinically relevant conditions, while eliminating surrounding planktonic (free-floating) microorganisms.  Other organisms tested included superbugs well-known for causing difficult-to-treat infections that tend to spread rapidly in healthcare settings:  Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus faecalis (VRE), Coagulase Negative Staphylococcus epidermidis (CONS), and Acinetobacter baumannii.


The evaluation was performed using Innovotech’s proprietary BEST Assay™ testing system, which is included in its scope of accreditation under ISO 17025:2017.  


About InnovoSIL™-1 Antimicrobial Silver

InnovoSIL™-1 antimicrobial silver possesses exceptional properties for efficacy against microbial biofilms as well as simplicity for coating onto or incorporating into medical devices, with favorable release characteristics. The unique structure around the silver present in the anion slows its inactivation by bodily fluids. Combining silver and iodine increases antimicrobial mechanisms of action, reducing the likelihood of a target developing resistance to it. InnovoSIL™-1 antimicrobial silver has demonstrated excellent stability under a wide variety of challenges and can be easily synthesized with high purity in a form that is simple to deposit onto metals or incorporate into wound dressings, gels, or polymers.  Innovotech is presently working with a number of industry collaborators who are pursuing a variety of applications for InnovoSIL™-1 antimicrobial silver.


About Innovotech

Innovotech is a Canadian biotechnology company owning proprietary intellectual property, conducting contract research, and owning and providing proprietary devices for testing in multiple applications in microbiology.  Innovotech can be found online at


“Patricia Nadworny”


Dr. Patricia Nadworny, Ph.D, B.Sc, P.Eng

Chief Scientific Officer and Quality & Safety Director

Innovotech Inc.

780-448-0585 ext. 7


This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company’s exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management’s assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.